All articles tagged with #alopecia areata
New treatments, including FDA-approved JAK inhibitors like Leqselvi, are revolutionizing the management of alopecia areata, an autoimmune disease causing hair loss, offering hope for significant hair regrowth for many patients, though challenges such as side effects and accessibility remain.
Science-backed methods to combat hair loss include platelet-rich plasma (PRP) injections to wake up dormant hair follicles, low-level laser therapy (LLLT) to stimulate hair growth, topical Minoxidil and oral Finasteride to treat pattern baldness, and JAK inhibitors to target alopecia areata, an autoimmune condition causing sudden hair loss. While a cure for baldness remains elusive, advancements in understanding and treating different forms of hair loss offer hope for those seeking to combat this common issue.
The FDA has approved LITFULO, a hair loss drug, to treat alopecia areata, an autoimmune disease that causes hair loss on the scalp, face, and body. The drug is approved for adults and adolescents aged 12 and over with severe alopecia areata. The drug inhibits two types of enzymes, blocking inflammatory signaling and cell-killing activity from T cells, which have been implicated in the development of alopecia areata. The clinical trial showed a statistically significant increase in hair coverage for those taking 50 mg of LITFULO compared to placebo.
A 2-year-old girl was diagnosed with alopecia areata, an autoimmune condition that attacks hair follicles, causing bald spots and thinning eyebrows. While there is no cure for alopecia, some treatments are available, including steroid pills, creams, shots, and a new systemic treatment. However, options for children are limited, and some treatments have side effects. Hair regrowth is unpredictable, and some hairs may grow back white at first. Stress is a significant factor in alopecia flare-ups or initiation, and children with eczema have an increased risk of developing alopecia.